|
|
|
|
| LEADER |
04286nmm a2200361 u 4500 |
| 001 |
EB001266239 |
| 003 |
EBX01000000000000000880823 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
161103 ||| eng |
| 020 |
|
|
|a 9783319321103
|
| 100 |
1 |
|
|a Pujade-Lauraine, Eric
|e [editor]
|
| 245 |
0 |
0 |
|a Ovarian Cancers
|h Elektronische Ressource
|b Advances through International Research Cooperation (GINECO, ENGOT, GCIG)
|c edited by Eric Pujade-Lauraine, Isabelle Ray-Coquard, Fabrice Lécuru
|
| 250 |
|
|
|a 1st ed. 2017
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2017, 2017
|
| 300 |
|
|
|a X, 286 p. 12 illus., 9 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Ovarian cancer management -- Clinical research in Europe dedicated to ovarian cancers -- Oncogenetics -- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality -- How to evaluate tumor burden before therapeutic decision -- Value of lymphadenectomy -- HYPEC: what is the evidence? -- Onco-fertility applied to ovarian cancers -- First-line systemic therapy (chemo/antiangiogenics) -- Elderly -- Treatment at relapse (surgery & systemic treatments) -- How to evaluate QoL -- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers -- Particular types of ovarian cancers -- High grade serous carcinoma & BRCA mutation anti-PARP -- Borderline and low grade carcinoma -- Clear Cell carcinoma -- Endometrioid carcinoma -- Mucinous carcinoma -- Carcinosarcoma -- Germ cell tumors -- Sex cord tumors -- Very rare ovarian malignant tumors including small cell carcinoma. Ovarian cancer management -- Clinical research in Europededicated to ovarian cancers -- Oncogenetics -- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality -- How to evaluate tumor burden before therapeutic decision -- Value of lymphadenectomy -- HYPEC: what is the evidence? -- Onco-fertility applied to ovarian cancers -- First-line systemic therapy (chemo/antiangiogenics) -- Elderly -- Treatment at relapse (surgery & systemic treatments) -- How to evaluate QoL -- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers -- Particular types of ovarian cancers -- High grade serous carcinoma & BRCA mutation anti-PARP -- Borderline and low grade carcinoma -- Clear Cell carcinoma -- Endometrioid carcinoma -- Mucinous carcinoma -- Carcinosarcoma -- Germ cell tumors -- Sex cord tumors -- Very rare ovarian malignant tumors including small cell carcinoma
|
| 653 |
|
|
|a Reproductive Medicine
|
| 653 |
|
|
|a Gynecology
|
| 653 |
|
|
|a Gynecology
|
| 653 |
|
|
|a Cancer Therapy
|
| 653 |
|
|
|a Reproductive health
|
| 653 |
|
|
|a Cancer / Treatment
|
| 653 |
|
|
|a Oncology
|
| 653 |
|
|
|a Pathology
|
| 700 |
1 |
|
|a Ray-Coquard, Isabelle
|e [editor]
|
| 700 |
1 |
|
|a Lécuru, Fabrice
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 028 |
5 |
0 |
|a 10.1007/978-3-319-32110-3
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-32110-3?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616,994
|
| 520 |
|
|
|a This book provides an overview of the latest developments in the concepts and management of ovarian cancer. The new data presented throughout opens the way to radically different therapeutic approaches. Surgery remains the core of ovarian cancer treatment, but its ultimate goal and the standard surgical procedure have evolved, giving rise to the question of how to label expert centers for debulking surgery. Neo-adjuvant chemotherapy is becoming more popular and is also a new field for testing novel drug combinations. Over recent years, ovarian cancer management has embraced molecular biology. It is now more correct to talk about cancers of the ovary rather than ovarian cancer, since it is not a unique disease but several entities with different molecular drivers. The significant advances in drugs targeting the microenvironment or the tumor cell DNA repair mechanisms are presented in detail together with exciting future perspectives. All these advances would not have been possible without collaborative groups such as the GINECO group in France and their integration in wider clinical research networks at the European (ENGOT) and international (GCIG) level
|